Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Daily News

Perfect Timing? Afternoon Valve Surgeries Have Fewer Complications

Michael O'Riordan

October 27, 2017

Podcast TCTMD Talking Points

PLATINUM DIVERSITY - Outcomes With Coronary Stenting in Women and Minorities

October 04, 2017

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Daily News

TAVR in the US: Regional Variations in Numbers, Outcomes

Michael O'Riordan

August 22, 2017

News Features

A Heart to Hold: 3-D Printers Add New Dimension to the Treatment of Structural Cardiac Disease

Yael L. Maxwell

August 02, 2017

News Daily News

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

Michael O'Riordan

July 17, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

Simple Frailty Test in TAVR Can Help Decide Not Just ‘If’ but ‘How’

Shelley Wood

July 07, 2017

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News CRT 2017

Pressure Wire Helps Identify Severe Aortic Stenosis in Paradoxical Low-Flow/Low-Gradient Cases

Michael O'Riordan

February 21, 2017

News Conference News CRT 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Michael O'Riordan

February 20, 2017

News Daily News

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Michael O'Riordan

February 09, 2017

Advertisement

Perfect Timing? Afternoon Valve Surgeries Have Fewer Complications

PLATINUM DIVERSITY - Outcomes With Coronary Stenting in Women and Minorities

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

TAVR in the US: Regional Variations in Numbers, Outcomes

A Heart to Hold: 3-D Printers Add New Dimension to the Treatment of Structural Cardiac Disease

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Simple Frailty Test in TAVR Can Help Decide Not Just ‘If’ but ‘How’

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Pressure Wire Helps Identify Severe Aortic Stenosis in Paradoxical Low-Flow/Low-Gradient Cases

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content